UK Teratology Information Service
Regional Drug & Therapeutics Centre
16-17 Framlington Place
Newcastle upon Tyne
NE2 4AB

Clinical enquiries: 0344 892 0909
General enquiries: 0191 213 7880

www.uktis.org

UKTIS OFFICIAL POSITION STATEMENT **September 2025**

Paracetamol in pregnancy and Autism Spectrum Disorder

Summary: Paracetamol is commonly used by pregnant women and is generally the drug of choice for treating pain and fever during pregnancy. Numerous studies have investigated neurodevelopmental outcomes following *in utero* exposure to paracetamol, with highly inconsistent results. A 2025 review of the pivotal epidemiological evidence concluded that *in utero* paracetamol exposure is unlikely to confer a clinically important increased risk of autism spectrum disorder (ASD), and that the current evidence does not warrant changes to clinical guidelines on the treatment of fever and pain in pregnancy. It is important that maternal pain and fever are adequately managed during pregnancy and where required, paracetamol use should not be avoided.

Further details:

- **Effective management of pain and fever in pregnancy is crucial.**
  - Pain and fever during pregnancy can affect the woman's physical and mental health, as well as her ability to carry out normal activities of daily living. Uncontrolled pain and fever can also have adverse effects on the developing fetus, and may increase the risk of outcomes such as miscarriage, malformation, growth restriction and preterm delivery. Access to safe and effective treatment is important for all pregnant women to minimise these potential risks.
- **Paracetamol is the drug of choice for the treatment of pain and fever during pregnancy:**
  - Other treatment options carry higher risks to both the woman and fetus. Non-steroidal anti-inflammatory drugs (NSAIDs), should not be routinely used from 20 weeks gestational age due to adverse fetal effects and tend to be avoided where possible earlier in pregnancy. Opioid analgesics can cause neonatal withdrawal effects/respiratory depression and carry a significant misuse potential, while gabapentinoids (pregabalin, gabapentin) lack adequate safety data and are not suitable options for the treatment of mild pain.
- **Evidence on paracetamol use in pregnancy and autism spectrum disorder (ASD) risk is highly inconsistent:**
  - A 2025 review of the pivotal epidemiological evidence concluded that *in utero* paracetamol exposure is unlikely to confer a clinically important increased risk

of ASD, and that the evidence does not warrant changes to clinical guidelines on the treatment of fever and pain in pregnancy.

- Most studies reporting associations between *in utero* paracetamol exposure and ASD are impacted by important biases. Methodological weaknesses include selection bias and inconsistencies in adjustment for confounding factors (co-variable risk factors for ASD), particularly genetic and familial factors which strongly influence the likelihood of ASD. Studies which employ exposure discordant siblings as comparators to control for shared genetic and environmental risk factors which influence ASD outcome, demonstrate substantially weaker or no associations, thereby indicating that study findings are heavily influenced by residual confounding (see Ahlqvist et al. 2024 and Gustavson et al. 2021 for further information).

Conclusion: UKTIS does not support the recent claims from the US administration relating to paracetamol use in pregnancy. There is no good evidence that paracetamol causes ASD and potential harm may arise from avoidance of paracetamol for pain and fever. It is recommended that pregnant women seek advice from their healthcare professional if they have concerns relating to paracetamol use.

Key references

Damkier P, Gram EB, Ceulemans M, Panchaud A, Cleary B, Chambers C, Weber-Schoendorfer C, Kennedy D, Hodson K, Grant KS, Diav-Citrin O, Običan SG, Shechtman S, Alwan S. Acetaminophen in Pregnancy and Attention-Deficit and Hyperactivity Disorder and Autism Spectrum Disorder. Obstet Gynecol. 2025 Feb 1;145(2):168-176. doi: 10.1097/AOG.0000000000005802. Epub 2024 Dec 5. PMID: 39637384.

Alemany S, Avella-Garcia C, Liew Z, Garcia-Esteban R, Inoue K, Cadman T, et al. Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms in childhood: Meta-analysis in six European population-based cohorts. European journal of epidemiology. 2021;36(10):993-1004.

Masarwa R, Levine H, Gorelik E, Reif S, Perlman A, Matok I. Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity Disorder and Autistic Spectrum Disorder: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Cohort Studies. American journal of epidemiology. 2018;187(8):1817-27.

Brandlistuen RE, Ystrom E, Nulman I, Koren G, Nordeng H. Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study. International journal of epidemiology. 2013.

Avella-Garcia CB, Julvez J, Fortuny J, Rebordosa C, Garcia-Esteban R, Galan IR, et al. Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms. International journal of epidemiology. 2016;45(6):1987-96.

Stergiakouli E, Thapar A, Davey Smith G. Association of Acetaminophen Use During Pregnancy With Behavioral Problems in Childhood: Evidence Against Confounding. JAMA Pediatr. 2016;170(10):964-70

Streissguth AP, Treder RP, Barr HM, Shepard TH, Bleyer WA, Sampson PD, et al. Aspirin and acetaminophen use by pregnant women and subsequent child IQ and attention decrements. Teratology. 1987;35(2):211-9.

Liew Z, Bach CC, Asarnow RF, Ritz B, Olsen J. Paracetamol use during pregnancy and attention and executive function in offspring at age 5 years. International journal of epidemiology. 2016;45(6):2009-17.

Ahlqvist VH, Sjöqvist H, Dalman C, Karlsson H, Stephansson O, Johansson S, Magnusson C, Gardner RM, Lee BK. Acetaminophen Use During Pregnancy and Children's Risk of Autism, ADHD, and Intellectual Disability. JAMA. 2024 Apr 9;331(14):1205-1214. doi: 10.1001/jama.2024.3172. PMID: 38592388; PMCID: PMC11004836.

Gustavson K, Ystrom E, Ask H, Ask Torvik F, Hornig M, Susser E, Lipkin WI, Lupattelli A, Stoltenberg C, Magnus P, Mjaaland S, Askeland RB, Walle KM, Bresnahan M, Nordeng H, Reichborn-Kjennerud T. Acetaminophen use during pregnancy and offspring attention deficit hyperactivity disorder - a longitudinal sibling control study. JCPP Adv. 2021 Jun 22;1(2):e12020. doi: 10.1002/jcv2.12020. PMID: 37431475; PMCID: PMC10242945.

UK Teratology Information Service. Therapeutic use of paracetamol in pregnancy. 2023 (version 2.0). Available from https://uktis.org/monographs/therapeutic-use-of-paracetamol-in-pregnancy/

UK Teratology Information Service. Use of non-steroidal anti-inflammatory drugs (NSAIDs) in pregnancy. 2023 (version 4.0). Available from https://uktis.org/monographs/use-of-non-steroidal-anti-inflammatory-drugs-nsaids-in-pregnancy/

UK Teratology Information Service. Pain management in pregnancy. 2019 (version 3.1). Available from https://uktis.org/monographs/pain-management-in-pregnancy/